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Abstract 
AIM: This study aims to determine the prognostic significance of phosphatase and tensin homolog (PTEN) loss in 
breast cancer. 
METHODS: We conducted a meta-analysis study. Sample of this study were research articles that evaluated 
PTEN loss and prognosis in breast cancer patients. We searched for relevant studies published in PubMed and 
Proquest from January 2010 to July 2018. We reviewed studies that examined the association between 
immunohistochemical expression of PTEN and breast cancer prognosis using meta-analysis methods. Pooled risk 
ratios (RR) were calculated using fixed and random-effect models. Data were processed using Review Manager 
5.3 (RevMan 5.3). 
RESULTS: There were 7 studies conducted a systematic review then continued to evaluate the association of 
PTEN loss and breast cancer prognosis by meta-analysis. There was a significant association of PTEN loss with 
poor prognosis of breast cancer (RR = 0.76 [95% CI 0.59-0.98 p <0.07), and there was not any significant 
publication bias for studies included. 
CONCLUSION: This study confirmed PTEN loss is an important independent factor for breast cancer prognosis. 
 
 
 
 
 
 
 
 
Introduction 
 
Breast cancer is the most common 
malignancies in women worldwide. Breast cancer 
incidents rapidly increased from 641,000 cases in 
1980 to 1.6 million cases in 2010 [1]. GLOBOCAN's 
2012 International Agency for Research on Cancer 
(IARC) data notes that there are approximately 1.67 
million new cases of BC diagnosed in 2012 or 25% of 
all cancers [2]. 
In Asia Pacific region breast cancer was the 
most common type of cancer among females, 
accounting for 18% of all cases in 2012, and was the 
fourth most common cause of cancer-related deaths 
(9%). Globally, one of three women (33%) diagnosed 
with breast cancer in a woman under 50 years old 
during 2008. The proportion of female breast cancer 
diagnosed among women under 50 years of age 
ranged from 21% to 58% in the Asia Pacific region [3].
 
Prognosis of breast cancer influenced by 
many factors. Prognostic factors such as tumour size, 
lymph node involvement and metastasis play a big 
role in prognosis. Standard adjuvant treatment 
reduces the risk of disease recurrence and improves 
prognosis [4]. Most relapses of breast cancer 
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occurred in the second year of treatment. About 
62.71% of patients with primary tumour ≥ 5 cm, 
79.65% of patients with ≥ 4 involved of axillary lymph 
nodes, and 72.41% of hormone receptor-negative 
tumours could relapse. Large tumour size, number 
axillary lymph nodes metastasis, and hormone 
receptor status were strongly associated with risk of 
relapse [5]. 
One biomarker of breast cancer growth is 
phosphatase and tensin homolog (PTEN). PTEN 
dysfunction on tumour cells causes increasing of NF-
kB activity resulting in growth, proliferation, survival, 
and metabolism of tumour cells [6], [7], [8]. Previous 
studies revealed tumour cells with PTEN loss of 
function have a poor prognosis [9], [10], [11], [12]. But 
there are also studies showed different results [13]. 
Changes of PTEN expression can be accurately 
identified by Immunohistochemical analysis (IHC). 
IHC analysis is quicker and more cost-effective than 
molecular genetic techniques to detect PTEN status. 
Therefore, this study aims to determine the prognostic 
significance of PTEN loss in breast cancer by IHC 
methods using meta-analysis. 
 
 
Material and Methods 
 
Study design and research sample 
This study was quantitative with meta-
analysis study design. The meta-analysis followed 
PRISMA (Preferred Reporting Items for Systematic 
Reviews and Meta-Analysis) Statement. Meta-
analysis was used to determine the association 
between PTEN loss expression and breast cancer 
prognosis. The result of published articles on the 
internet through databased on PubMed and Proquest 
that published from January 2010 to August 2018 
were analysed. The inclusion criteria of this study 
were cohort studies. Exclusion criteria of this study 
were articles which are not available in full-text form. 
 
Operational definitions 
The variables of this study are PTEN loss 
expression as an independent variable, and a 
dependent variable is a prognosis. 
 
Research procedure 
This study was conducted by collecting data 
through the identification of published research 
articles on the association between PTEN loss 
expression and breast cancer prognosis by using the 
PubMed and Proquest search engines (Figure 1). 
 
 
Figure 1: Flow diagram research procedure 
 
Identification of 5,725 articles, reviewed 
through the title of the articles, continued by reviewing 
the abstract, and then the full-text form. The article 
was excluded if: (a) not the relevant subject outcome, 
(b) the information provided in the results was 
insufficient for data extraction and (c) duplicate 
studies. 
 
Data collection technique 
The search was limited to English language 
articles. The article type was limited to research 
articles. The research subject was limited to a human 
subject. The time of publication was limited from 
January 2010 to August 2018 period. The abstract of 
articles with relevant title continued to review process, 
and the articles with the irrelevant title were excluded. 
After that, articles with relevant abstract were 
continued to be reviewed in full-text, while the others 
were excluded. The articles that used 
immunohistochemistry method only and the relevant 
outcome will be reviewed and analysed.  
 
Data analysis  
The analysis was conducted to obtain the 
value of pooled risk ratio as the combined risk ratio 
value from the collected researches. Data analysis 
was performed using the Mantel-Haenszel method 
with a fixed-effect model and the DerSimonian-Laird 
random-effect model. Publication bias was visually 
evaluated by using funnel plots and statistically 
assessed through Egger’s and Begg’s tests. Meta-
analysis was carried out by using Review Manager 
5.3 (RevMan 5.3). 
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Results 
 
The selection of studies was conducted to 
identify 7 studies related to the PTEN loss expression. 
The characteristic of eligible studies (Table 1). These 
publications estimate association between PTEN loss 
expression and prognosis with various sample size, 
staining methods, cut off and methods of 
interpretation. 
Table 1. A systematic review of the role of loss of PTEN 
expression in breast cancer prognosis 
First Author Procedure Histology 
typing 
Cut off Staining 
methods 
Number of 
patients 
Scoring Outcome 
Jensen et al., 
[11] 
IHC mixed > 40 Cytoplasmic 235 IRS OS 
Wu et al., [14] IHC TN > 5 Cytoplasmic 65 IRS OS 
Perez et al., 
[15]  
IHC mixed > 0 Nuclear / 
cytoplasmic 
1286 SI DFS/OS 
Tang et al., [16] IHC mixed > 0 inti 68 SI OS 
Beelen et al., 
[17] 
IHC mixed > 3 Cytoplasmic 436 SI OS 
Stern et al., 
[18] 
IHC mixed > 5 Cytoplasmic 2354 SI DFS/OS 
Beg et al., [19] IHC Mixed > 90 Nuclear and 
cytoplasmic 
957 H-score OS 
Abbreviation: IHC: Immunohistochemistry; TN: Triple-negative; IRS; immunoreactive score; SI: Staining 
intensity; OS: overall survival; DFS: disease-free survival. 
  
Forest plots of PTEN loss expression in 
breast cancer prognosis (Figure 2). Figure 2 revealed 
the significance association of PTEN loss expression 
with prognosis of breast cancer (RR = 0.76 [95% CI = 
0.59-0.98, p < 0.07]). 
 
Figure 2: Forest plots the association of PTEN loss and breast 
cancer prognosis 
 
Funnel plot association of PTEN loss 
expression with breast cancer prognosis (Figure 3).  
 
Figure 3: Funnel plots the association of PTEN loss and breast 
cancer prognosis 
Figure 3 showed the association of PTEN loss 
expression with the prognosis of breast cancer has a 
variety of homogeneous research on breast cancer. It 
means that if the analysis is done on the population, 
time and place and different conditions the results will 
be consistent. There was not any significant 
publication bias for the association of PTEN loss 
expression with breast cancer prognosis, Egger’s test 
(P = 0.784) and Begg’s test (P = 0.881). 
 
 
Discussion 
 
Identification of biomarkers and gene 
expressions are needed to improve early diagnosis 
and prognosis, as well as to provide the most effective 
drug suitable with molecular characteristics of the 
patients. Studies over the years have indicated that 
prognostic and predictive biomarkers are molecules 
involved in the regulation of cellular mechanisms, 
including proliferation, apoptosis, angiogenesis, 
metastasis and therapeutic resistance. Evidence has 
shown that PTEN is an important factor in many 
processes related to cancer progression [20], [21]. 
PTEN is one of the tumour suppressor genes 
that play a role in breast cancer development. PTEN 
is an antagonist of phosphatidylinositol 3-kinase 
(PI3K) and plays a role in dephosphorylation of PIP3 
into PIP2. Loss of PTEN can cause overgrowth, 
proliferation, survival, and metabolism of tumour cells. 
PTEN consists of phosphatase homolog and 
cytoskeletal tensin protein. PTEN protein contains 403 
amino acids. The crystal structure of PTEN consists of 
two main functional domains (phosphatase domain 
and C2 domain) and three structural PIP2 binding 
domains, C-terminal tail [22]. PTEN loss can also 
cause phosphorylation mediated by Akt and increase 
of NF-kB activity which promotes P53 degradation. 
P53 degradation reduced the apoptotic ability and 
induced cell cycle progression [8]. PTEN gene located 
on chromosome 10q23. Loss of heterozygosity on 
chromosome 10q23 often occurs in advanced 
sporadic tumours, including breast cancer [23]. PTEN 
dysfunction, especially its inactivity in tumour cells, 
causes PIP3 accumulation in cells and regulate Akt 
recruitment. Furthermore, it can activate downstream 
kinases, increasing NF-kB activity resulting in growth, 
proliferation, survival, and metabolism of tumour cells 
[6], [7], [24]. 
Some studies suggested PTEN loss in tumour 
cells are associated with drug resistance [6,15]. Other 
studies showed a significant association between 
PTEN immunoscoring and mRNA expression. A 
previous study also revealed that PTEN loss has a 
significantly worse prognosis than PTEN positive 
breast cancer cells [17], [18]. PTEN loss is also 
associated with aggressive behaviour and poor 
prognosis [14], [19]. 
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Changes of PTEN expression can be 
identified by IHC analysis, Fluorescent In situ 
Hybridization (FISH) and PCR. There were previous 
meta-analyses of PTEN loss, but it did not elaborate 
on the methods. The previous study found IHC 
analysis is quicker and more cost-effective than 
molecular genetic techniques to detect PTEN 
expression [25], [26]. FISH and PCR is limited to 
sophisticated laboratories; it cannot be done routinely. 
In a developing country, not all laboratories have FISH 
and PCR services. This study answers the need for 
an analysis of the association of PTEN with prognosis 
in the use of IHC staining methods.  
This study has identified the heterogeneity of 
published articles (p = 0,04, I
2 
= 45%), then used the 
random effect models. The analysis revealed 
significance association of PTEN loss with prognosis 
of breast cancer (RR = 0.76 [95% CI = 0.59-0.98, p < 
0.07]). The pooled finding of these seven articles 
provides evidence of the significance of PTEN loss of 
expression with prognosis. This meta-analysis 
showed that PTEN could provide prognostic 
information for the clinician during the decision-
making process. 
Although we try to make our study as good as 
possible, the limitation of this study should be 
considered. First, data suitability of several studies 
included in this meta-analysis showed different 
sample sizes (65-2354 samples). Second, there are 
different scoring methods for PTEN status with 
different numbers of positivity of tumour cells. The 
study was using immunohistochemical analysis and 
could be carried out with different evaluation methods 
using IS (intensity staining), histoscore (H-score) and 
percentage of positive cells. Different studies with 
different PTEN classifications and different patient 
sets are hardly comparable.  
Cut off points are varying from > 0% to > 
90%. These differences in the method could be 
responsible for various PTEN expression observed in 
tumour cells. Although the robustness of PTEN 
antibodies has been controversy, optimal IHC 
conditions including concentration of anti-PTEN 
antibody as well as different antigen retrieval 
conditions should be considered too. Scoring methods 
against PTEN's requires a more valid and reliable 
standard methodology to assess PTEN expression. In 
conclusion, the result of this meta-analysis showed 
that loss PTEN expression is associated with poor 
prognosis of breast cancer.  
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